



Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?

Margherita Giannini¹, Mickael Ohana², Benoit Nespola³,
Giovanni Zanframundo^{4,5}, Bernard Geny^{1,6} and Alain Meyer^{1,6,7}

Affiliations: ¹Physiology and Functional Explorations Dept, University Hospitals of Strasbourg, Strasbourg, France. ²Radiology Dept, Nouvel Hôpital Civil, University Hospitals of Strasbourg, Strasbourg, France. ³Laboratory of Immunology, Nouvel Hôpital Civil, University Hospitals of Strasbourg, Strasbourg, France. ⁴Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. ⁵Dept of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy. ⁶Federation of Translational Medicine of Strasbourg, Strasbourg University, Strasbourg, France. ⁷Rheumatology Dept, National Centre for Rare Systemic Autoimmune Diseases, University Hospitals of Strasbourg, Strasbourg, France.

Correspondence: Alain Meyer, Rheumatology Dept, National Centre for Rare Systemic Autoimmune Diseases, University Hospitals of Strasbourg, 1 avenue Molière, Strasbourg 67098, France. E-mail: alain.meyer1@chru-strasbourg.fr



@ERSpublications

Similarities between COVID-19 and anti-MDA5 syndrome support further evaluation of employing an immunomodulatory strategy in COVID-19 <https://bit.ly/3dN6lJ8>

Cite this article as: Giannini M, Ohana M, Nespola B, *et al.* Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?. *Eur Respir J* 2020; 56: 2001618 [<https://doi.org/10.1183/13993003.01618-2020>].

This single-page version can be shared freely online.

To the Editor:

The coronavirus disease 2019 (COVID-19) pandemic has struck worldwide, leading to more than 7 million cases by June 2020, with a ~5.5% mortality rate, mainly due to acute respiratory distress syndrome (ARDS) [1].